Science and Tech

Myelodysplastic Syndrome Treatment Market to Worth $ 5.7 Billion by 2025 | CAGR: 12.7%


Myelodysplastic-Syndrome-Treatment 838.jpg

The Global Myelodysplastic Syndrome Treatment Market was valued at US$ 2,213.2 million in 2017 and is projected to expand at a CAGR of 12.7% during the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights. Growing incidence of the bone marrow disorders and cytogenetic abnormalities expected to be the major factor driving growth of the global myelodysplastic syndrome treatment market over the foreseeable future.

According to a report published in 2015 by American Cancer Society, myelodysplastic syndromes occurs at the rate of 4.8 cases per 100,000 people, which counts up to 13,000 new cases of MDS in the U.S. every year. The report also states that this number has witnessed an increase in the last few years as the average population is ageing every consecutive year. Moreover, the fact report 2014-2015 published by Leukemia and Lymphoma Society suggests that the overall incidence of MDS in the U.S. by gender are 6.7 per 100,000 in male while 3.8 per 100,000 in females.

To get holistic SAMPLE with TOC @ https://www.coherentmarketinsights.com/insight/request-sample/775

Myelodysplastic syndrome (MDS) refers to the closely related group of hematopoietic clonal disorders that are majorly observed among the geriatric population. The myelodysplastic syndromes rarely exhibit any symptoms during their earlier stages. Treatments of the MDS usually focuses on either preventing or reducing the complications of the disease with the drug therapies available in the market. This includes Vidaza (Azacitidine), Revlimid (Lenalidomide), Decitabine (Dacogen), and Deferasirox (Jadenu). In cases with extreme impairments of bone marrow, MDS are treated by a bone marrow transplant.

The World Health Organization (WHO) classifies various types of MDS according to clinical features, peripheral blood and bone marrow findings and cytogenetic analysis which shares features of MDS and myeloproliferative neoplasms as follows:

Chronic myelomonocytic leukemia (CMML-1 and CMML-2),Atypical chronic myeloid leukemia (CML), Bcr-Abl1 negative,Juvenile myelomonocytic leukemia (JMML),MDS/MPN, unclassifiable

Most of the people suffering with MDS has primary MDS that is usually devoid of a triggering event. One possible cause for MDS could be repetitive exposure to benzene.

Treatments include drug therapy with newer agents, blood transfusion and administration of blood cell growth factors among others. The symptoms are treated with various approved drugs such as Vidaza (Azacitidine), Revlimid (Lenalidomide), Decitabine (Dacogen), and Deferasirox (Exjade). Vidaza (Azacitidine) was the first approved drug by the U.S. Food and Drug Administration for the treatment of MDS. It is indicated for treatment of both high and low risk patients with all subtypes of MDS. Furthermore, companies such as Celgene Corporation are focusing on development of drug therapies for MDS with specific indications such as MDS with deletion 5q and post HMA failure with drugs Durvalumab and Luspatercept in the late clinical phases.

Key Takeaways of the Myelodysplastic Syndrome Treatment Market:

The global myelodysplastic syndrome treatment market is expected to expand at a CAGR of 12.7% during the forecast period (2016–2025), as there exists a huge potential market, especially in Asia Pacific, Latin America, Middle East, and Africa

Robust development in drug therapies, drugs showing potential in pipeline and inclusion of generic versions of the branded products in the market due to patent expiries are expected to drive the global myelodysplastic syndrome market

Some of the major players involved in the global myelodysplastic syndrome treatment market are Celgene Corporation, Novartis AG and Otsuka, Astellas, Astex, Acceleron Pharma, Onconova Pharmaceuticals, GlaxoSmithKline Plc, Pfizer, Inc., Eli-Lilly and CTI Biopharma

Complete Report Details @ https://www.coherentmarketinsights.com/market-insight/myelodysplastic-syndrome-treatment-market-775

Catch us at 3rd International Conference on Separation + Drying Technologies for Milk & Whey at Cologne, March 19 and 20, 2018”

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, 
#3200 
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Visit our news Website: http://www.coherentchronicle.com





Coherent Market Insights

AbhijitR

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.